News | April 29, 2023
TPAG organizes Thalassemia & SCD prevention discussion
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Apollo continues to invest in genomics technology and research for better patient care
Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride levels
SÜDPACK is setting standards in terms of both performance and sustainability
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Subscribe To Our Newsletter & Stay Updated
